Printer Friendly

ROBERTS PHARMACEUTICAL REPORTS RECORD LEVEL FIRST QUARTER SALES

 ROBERTS PHARMACEUTICAL REPORTS RECORD LEVEL FIRST QUARTER SALES
 EATONTOWN, N.J. May 19 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) reported today that total revenues for the three month period ended March 31, 1992, reached a record level of $5.2 million, an increase of 286 percent, or $3.4 million above the $1.8 million for the comparable period in 1991. For the first three months of 1992, product sales were $4.5 million; an increase of $3.1 million from the $1.4 million recorded in 1991 with prescription products accounting for $3.3 million or 73 percent of total product sales.
 The company's operating expenses of $4.4 million for the three month period ended March 31, 1992, were $1.6 million higher than the $2.8 million level for the same period in 1991. The increased level of operating expenses for the three month period of 1992 reflects the company's continued and expanded investment in product development for late development stage prescription products and marketing and promotional expenditures in support of currently marketed products. The primary operating expense increases were as follows: $560,000 in increased marketing and sales promotion programs; $418,000 increase in product development programs; and $210,000 increase in non-cash charges related to the amortization of intangibles from recent product acquisitions.
 The net loss for the three month period in 1992 or $1.1 million was $500,000, or 31 percent less than the $1.6 million loss for the comparable 1991 period. The 1992 first quarter loss of 10 cents per share on 10.8 million average shares outstanding compares to the loss of 21 cents per share on 7.5 million average shares outstanding for the same period in 1991.
 As of March 31, 1992, the company had total assets of $143.6 million with $105.2 million in cash and liquid investments compared with $44.1 million in total assets and $14.2 million in cash and liquid investments at year end 1991.
 In commenting on these results, Dr. Robert A. Vukovich,, chairman and CEO, said, "We expect our revenue base to continue to increase as our marketing and sales programs are fully implemented. We are in a solid financial position, and substantial progress is being made on our programs as we continue to implement our growth plan."
 Roberts Pharmaceutical Corporation is engaged in the business of acquiring, developing and marketing human pharmaceuticals in the United States and abroad. The company is developing late stage pharmaceuticals for the treatment of cancer, respiratory disease, endocrine disorders, pain management, cardiovascular and urologic conditions. Roberts currently markets a line of prescription and non-prescription pharmaceuticals in the United States and abroad.
 ROBERTS PHARMACEUTICAL CORPORATION
 (Unaudited -- Amounts in thousands, except per share data)
 Balance Sheet Data
 First quarter ended: 3/31/92 12/31/91
 Assets:
 Cash and marketable securities $105,233 $14,161
 Other current assets 7,534 5,600
 Other assets 30,823 24,389
 Total assets 143,590 44,150
 Liabilities & Stockholders' Equity:
 Current liabilities 10,261 9,807
 Long-term debt 8,151 9,237
 Stockholders' equity 125,178 25,106
 Total liabilities & stockholders' equity $143,590 44,150
 Operating Statement Data
 Three months ended March 31: 1992 1991
 Revenues:
 Product sales $ 4,545 $ 1,381
 Licenses, interest and other 697 450
 Total 5,242 1,831
 Net income (loss) (1,095) (1,594)
 Income (loss) per common share ($.10) ($.21)
 Wtd. avg. common shares outstanding 10,843 7,498
 -0- 5/19/92
 /CONTACT: Anthony P. Maris of Roberts Pharmaceutical, 908-389-1182/
 (RPCX) CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU: ERN


PS-TS -- NY056 -- 1820 05/19/92 12:18 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 19, 1992
Words:611
Previous Article:CYTOGEN ANNOUNCES 1992 ANNUAL MEETING HIGHLIGHTS
Next Article:MAC POS MAKING INROADS WITH QUICK-SERVE CATEGORY; BURGER KING, McDONALD'S AND ROY ROGERS UNITS HAVE SYSTEM
Topics:


Related Articles
ROBERTS PHARMACEUTICALS ANNOUNCES THIRD QUARTER RESULTS
ROBERTS PHARMACEUTICAL ANNOUNCES SECOND QUARTER RESULTS
ROBERTS PHARMACEUTICAL CORPORATION REPORTS RECORD 1992 SALES RESULTS
ROBERTS PHARMACEUTICAL CORPORATION REPORTS PROFITABLE FIRST QUARTER RESULTS
ROBERTS PHARMACEUTICAL CORPORATION REPORTS RECORD SALES AND PROFITS
ROBERTS PHARMACEUTICAL CORPORATION REPORTS RECORD 1993 SALES AND PROFIT RESULTS
ROBERTS PHARMACEUTICAL CORPORATION REPORTS FIFTH STRAIGHT QUARTER OF PROFITABLE EARNINGS
ROBERTS COMMENTS ON PRELIMINARY RESULTS FOR FIRST TWO MONTHS OF SECOND QUARTER
Roberts Pharmaceutical Corporation Reports First Quarter 1997 Profit And A 53% Year-To-Year Advance In Revenues
Roberts Pharmaceutical Corporation Reports Strong First Quarter Results;.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters